Volume 85, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24–50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7–40 months).


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S, 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581596.[Crossref]
    [Google Scholar]
  2. Camargo RA, Tuon FF, Sumi DV, Gebrim EM, Imamura R, Nicodemo AC, Cerri GG, Amato VS, 2010. Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses. Am J Trop Med Hyg 83: 515518.[Crossref]
    [Google Scholar]
  3. Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA, 2007. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 77: 266274.
    [Google Scholar]
  4. Nonata R, Sampaio R, Marsden PD, 1997. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Trans R Soc Trop Med Hyg 91: 77.[Crossref]
    [Google Scholar]
  5. Amato VS, Nicodemo AC, Amato JG, Boulos M, Neto VA, 2000. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemother 46: 341342.[Crossref]
    [Google Scholar]
  6. Amato VS, Tuon FF, Imamura R, Abegão de Camargo R, Duarte MI, Neto VA, 2009. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 23: 10261034.[Crossref]
    [Google Scholar]
  7. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 43: 917924.[Crossref]
    [Google Scholar]
  8. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F, 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomized controlled trial. Lancet 377: 477486.[Crossref]
    [Google Scholar]
  9. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377383.[Crossref]
    [Google Scholar]
  10. Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, Bellmann R, 2006. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 57: 11531160.[Crossref]
    [Google Scholar]
  11. WHO, 2010. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, 2226 March 2010, Geneva.
    [Google Scholar]

Data & Media loading...

  • Received : 03 May 2011
  • Accepted : 25 Jul 2011
  • Published online : 01 Nov 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error